Contineum Therapeutics In... (CTNM)
NASDAQ: CTNM
· Real-Time Price · USD
8.12
0.74 (10.03%)
At close: Aug 18, 2025, 3:03 PM
Contineum Therapeutics Class A Common Stock Income Statement
Financials in USD. Fiscal
year is
undefined.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 50M | n/a | n/a |
Cost of Revenue | 79K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 42K | 73K | 81K |
Gross Profit | -79K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 49.96M | -73K | -81K |
Operating Income | -17.9M | -18.11M | 84.74M | -12.97M | -10.94M | -9.93M | -9.68M | -8.07M | 38.94M | -5.12M | -5.45M |
Interest Income | 2.03M | 2.25M | 2.53M | 2.74M | 2M | 1.64M | 1.79M | 1.74M | 679K | 401K | 342K |
Pretax Income | -16.04M | -15.99M | -14.56M | -10.27M | -9.01M | -8.42M | -7.93M | -6.37M | 42.29M | -4.82M | -7.51M |
Net Income | -16.04M | -15.99M | -14.56M | -10.27M | -9.01M | -8.42M | -7.77M | -6.25M | 41.56M | -4.82M | -7.51M |
Selling & General & Admin | 3.84M | 4.4M | 4.03M | 3.25M | 3.04M | 2.15M | 1.66M | 1.57M | 1.6M | 1.48M | 1.71M |
Research & Development | 13.98M | 13.71M | 13.02M | 9.73M | 7.9M | 7.78M | 8.01M | 6.5M | 9.46M | 3.63M | 3.95M |
Other Expenses | n/a | n/a | -101.79M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -10K |
Operating Expenses | 17.82M | 18.11M | -84.74M | 12.97M | 10.94M | 9.93M | 9.68M | 8.07M | 11.06M | 5.12M | 5.37M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 116K | 92K | 101K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 213K |
Cost & Expenses | 17.9M | 18.11M | -84.74M | 12.97M | 10.94M | 9.93M | 9.68M | 8.07M | 11.06M | 5.12M | 5.45M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | -161K | -118K | 729K | n/a | n/a |
Shares Outstanding (Basic) | 25.9M | 25.87M | 25.85M | 25.73M | 25.72M | 25.72M | 25.13M | 25.43M | 25.72M | 25.72M | 25.13M |
Shares Outstanding (Diluted) | 25.9M | 25.87M | 25.85M | 25.73M | 25.72M | 25.72M | 25.13M | 25.43M | 25.72M | 25.72M | 25.13M |
EPS (Basic) | -0.62 | -0.62 | -0.65 | -0.4 | -0.35 | -0.33 | -0.31 | -0.25 | 1.62 | -0.19 | -0.3 |
EPS (Diluted) | -0.62 | -0.62 | -0.65 | -0.4 | -0.35 | -0.33 | -0.31 | -0.25 | 1.62 | -0.19 | -0.3 |
EBITDA | -15.96M | -18.03M | -14.49M | -10.21M | -8.95M | -9.87M | -7.89M | -6.33M | 42.45M | -4.66M | -7.33M |
EBIT | -16.04M | -18.11M | -14.56M | -10.27M | -9.01M | -9.93M | -7.93M | -6.37M | 42.41M | -4.73M | -7.41M |
Depreciation & Amortization | 79K | 78K | 75K | 62K | 60K | 61K | 37K | 43K | 42K | 73K | 81K |